Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Journal of Clinical Oncology · 10.03.2025 · 43 (8) · 938-948
DOI: 10.1200/jco.24.00400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2025. Verfasst von Georgina V Long und 24 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination or monotherapy pooled across all major company-sponsored trials, as well as clinical factors associated with survival, in patients with immune checkpoint inhibitor (ICI) treatment–naïve unresectable/metastatic melanoma. METHODS Data were pooled from six CheckMate studies in ICI treatment–naïve patients receiving NIVO + IPI (NIVO 1 mg/kg + IPI 3 mg/kg or NIVO 3 mg/kg + IPI 1 mg/kg) or NIVO monotherapy (3 mg/kg). OS was assessed for each treatment, as well as in select subgroups. Cox proportional multivariate analysis (MVA) and classification and regression tree (CART) analyses were performed within treatment arms. RESULTS Median follow-up for OS was 45.0 months for patients treated with NIVO + IPI (n = 839) and 35.8 months for patients treated with NIVO (n = 536). OS was longer with NIVO + IPI versus NIVO monotherapy (hazard ratio, 0.78 [95% CI, 0.67 to 0.91]), with 6-year OS rates of 52% versus 41%, respectively. Consistent benefit was observed in BRAF -mutant and BRAF -wild-type patients and those with normal and elevated lactate dehydrogenase (LDH). Numerical difference in OS was also observed across PD-L1 expression levels, although more pronounced with no/low PD-L1 expression. Clinical factors associated with decreased survival in both the MVA and CART analyses were LDH > upper limit of normal with either treatment, age ≥65 years with NIVO + IPI, and the presence of liver metastases with NIVO monotherapy. CONCLUSION In this large, pooled nonrandomized retrospective analysis, we observed that NIVO + IPI provides longer OS than NIVO in patients with ICI treatment–naïve advanced melanoma and identifies clinical factors that appear to be associated with survival for each treatment, which may assist with treatment decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.
- The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
- University Hospital, German Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
- Aix-Marseille University, AP-HM, Timone, Marseille, France.
- University of Michigan, Ann Arbor, MI.
- Hospital General Universitario Gregorio Marañon, Madrid, Spain.
ORCID-Profile: Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Iván Márquez-Rodas, John Wagstaff, Céleste Lebbé, Jacopo Pigozzo, Caroline Robert, Paolo A Ascierto, Michael A Postow, Michael B Atkins, Mario Sznol, Suzanne L Topalian, Srividya Kotapati, Pratik K Thakkar, Corey Ritchings
Förderung
- NCI NIH HHS
Zitieren
APA
Long, G. V., Larkin, J., Schadendorf, D., Grob, J. J., Lao, C. D., Márquez-Rodas, I., Wagstaff, J., Lebbé, C., Pigozzo, J., Robert, C., Ascierto, P. A., Atkinson, V., Postow, M. A., Atkins, M. B., Sznol, M., Callahan, M. K., Topalian, S. L., Sosman, J. A., Kotapati, S., …, & Hodi, F. S. (2025). Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. Journal of Clinical Oncology, 43(8), 938-948. https://doi.org/10.1200/jco.24.00400
Vancouver
Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, et al. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. Journal of Clinical Oncology. 2025;43(8):938-948. doi:10.1200/jco.24.00400
BibTeX
@article{Long2025,
author = {Long, Georgina V and Larkin, James and Schadendorf, Dirk and Grob, Jean-Jacques and Lao, Christopher D and Márquez-Rodas, Iván and Wagstaff, John and Lebbé, Céleste and Pigozzo, Jacopo and Robert, Caroline and Ascierto, Paolo A and Atkinson, Victoria and Postow, Michael A and Atkins, Michael B and Sznol, Mario and Callahan, Margaret K and Topalian, Suzanne L and Sosman, Jeffrey A and Kotapati, Srividya and Thakkar, Pratik K and Ritchings, Corey and Pe Benito, Melanie and Re, Sandra and Soleymani, Samira and Hodi, F Stephen},
title = {Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {8},
pages = {938--948},
doi = {10.1200/jco.24.00400}
}
EUVIMED